Acute & chronic heart failure are still lacking effective therapeutics
Novel
therapies in acute and chronic heart failure.
Pharmacology &
Therapeutics 135:1-17, 2012.
Despite past advances in the pharmacological management
of heart failure, the prognosis of these patients remains poor, and for many,
treatment options remain unsatisfactory. Additionally, the treatments and
clinical outcomes of patients with acute decompensated heart failure have not
changed substantially over the past few decades. Consequently, there is a
critical need for new drugs that can improve clinical outcomes.
Heart failure is an abnormality of
the structure or function of the heart. Even in a normal environment, the heart
is unable to supply enough oxygen for organ metabolism. Typical symptoms of
heart failure include shortness of breath (dyspnea), leg swelling, fatigue, an
increase in jugular venous pressure, pulmonary edema, and apical impulse
movement. Cardiac anomalies may result
from abnormalities in left ventricular systolic or diastolic function, the
heart valve, the coronary artery, pericardium, endocardium, and rhythm and
conduction. In developing countries, 1-2% of adults have heart failure. Among
adults above the age of 70, prevalence is as high as 10%. Despite the improved
drug therapy for heart failure, prognosis for patients is not improving, and as
a result, neither doctor nor patient is satisfied. Particularly in acute
decompensated heart failure patients, clinical treatment has not improved in
decades. Therefore, new drug development is the key to a turning point in
clinical treatment of patients with heart failure.
The major
existing heart failure drugs are Angiotensin-converting enzymes, beta blockers,
Mineralo-corticoid/aldosterone receptor antagonists, Angiotensin receptor
blockers, Ivabradine, digoxin, and diuretics.
In the treatment of acute heart failure, there are also new inotrops
such as cardiac myosin enhancers and relaxin in development. For chronic heart
failure, new drugs such as renin-angiotensin-aldosterone system inhibitors,
ryanodine receptor stabilizers, and SERCA enhancers are currently in
development. For heart failure-related pulmonary hypertension and anemia, there
remains a lack of effective treatments to improve these related conditions. The
drugs currently used in clinical trials can potentially either temporarily
relieve symptoms of heart failure, or be used as prevention towards the continued
deterioration of acute or chronic heart failure. However, their ability to
improve the underlying causes of heart failure still remains unclear. As posted
in the latest International Journal, heart failure drug development is still
facing a bottleneck.
The AcaMed company’s R&D
team discovered, in anti-aging medicine from ancient books of traditional
Chinese medicine, that almost all non-hematopoietic cells can promote ribosome
synthesis and induce hormone production in dimer hemoglobin. Dimer hemoglobin’s
ability to carry oxygen is much higher than the tetramer hemoglobin that exists
in the red blood cell. Our product uniquely delivers a dual mechanism for
supplying your cells with adequate supplies of ATP energy and oxygen that lead
to the restoration cell function. This accomplishment has never been achieved
so far worldwide. We have used the internationally recognized research
model of heart failure in mice, validated by ultrasound and electrocardiogram of the
heart, to confirm that our
ingredients can allow mice
to fully restore previously injured heart function. This result was
categorized as addressing an “unmet need” and recognized as an unprecedented therapeutic drug rather than a preventive drug upon the submission to top international academic journals. Our research has been published in British Journal
of Pharmacology in 2013. AcaMed will team up with university hospitals to perform clinical trials further.
The product “SporT-101” is based on traditional oriental medicine’s principle of promoting the
functions of various cells and the body. Some mountain climber response
that our SporT-101 is a wonder product and let them felt full with energy
during their mountain climb duration, especially acute mountain sickness was greatly
reduced. Wishing our members health and happiness!
http://www.acamed.com.tw/